About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT02774161

B-mode Ultrasound Imaging in Detecting Early Liver Cancer

This pilot trial studies how well B-mode ultrasound imaging works in detecting liver cancer that is early in its growth and may not have spread to other parts of the body. Diagnostic procedures, such ...

Lead sponsor: Stanford University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Stanford University

PRIMARY OBJECTIVES: I. To investigate the use of quantitative ultrasound spectroscopy to detect early hepatocellular carcinoma (HCC) as an inexpensive and widely available quantitative (i.e. robust) method to confirm disease in developing countries. OUTLINE: Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•For Healthy Volunteers
•1. Patients over 18 years of age.
•2. Must have no known medical problems and have had a full medical exam within 6 months of the study. If healthy volunteers have not had a full medical exam within 6 months of the study, one of the ultrasound physicians will conduct the medical exam prior to any study procedures.
•For HCC patients
•1. Patients over 18 years of age.
•2. Patient with confirmed diagnosis of HCC, and untreated or Patients with Suspected HCC (Suspected HCC nodules should preferably be smaller than 3 cm and preferably within 6 cm in depth of the transducer head to minimize attenuation) and untreated or Patients at a higher risk of HCC undergoing a screening program by Ultrasound.

Exclusion Criteria

•For Healthy volunteers
•1\. Patients who are not likely to comply with the protocol requirements.
•For HCC patients
•1. Patients should not be taking other Investigational Agents.
•2. Concomitant medications for treatment of the target lesion.

Related studies

Natural History of Noncirrhotic Portal Hypertension

NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more

RECRUITINGPhase 2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383 · Interstitial Lung Disease, Pulmonary Fibrosis

RECRUITINGPhase 1/2

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

NCT07281781 · Myelofibrosis, Myelofibrosis; Anemia

Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)

NCT06345547 · Sarcopenia, Cirrhosis, and more

RECRUITINGPhase 1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 3, 2021Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment45

Start dateMay 2016

Last updatedAug 3, 2021

Condition

Cirrhosis Early Hepatocellular Carcinoma Fibrosis Stage I Hepatocellular Carcinoma Stage II Hepatocellular Carcinoma

Locations shown

Stanford University, School of Medicine

Palo Alto, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 3, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions